Table of Contents Author Guidelines Submit a Manuscript
Canadian Respiratory Journal
Volume 3 (1996), Issue 5, Pages 295-300
Original Article

Clinical Experience in the Use of Inhaled Nitric Oxide in Infants with Pulmonary Hypertension

Robert P Lemke, Jaques Belik, Niels G Giddins, and Carlos A Fajardo

Departments of Neonatology, Winnipeg Children’s Hospital, and The Variety Children’s Heart Centre, Winnipeg, Manitoba, Canada

Copyright © 1996 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Inhaled nitric oxide (iNO) is a potent local vasodilator. Numerous case reports describe its efficacy in treating persistent pulmonary hypertension of the newborn (PPHN). This report describes experience at the authors' institution with iNO therapy in 10 consecutive infants with PPHN of a number of etiologies. Infants received iNO at doses of 0.2 to 80 ppm for 1 to 481 h. Five infants were classified as responders (20 torr or greater rise in PaO2) and one as a partial responder (PaO2 rise of 10 to 19 torr). The remaining four did not respond. Overall observed mortality was three of 10, with two of four of nonresponders and the only partial responder dying. Survivors required ventilation for 18±18 days and oxygen for 29±30 days, and they remained in hospital 40±30 days (mean ± SD). Although improvement in oxygenation with iNO was primarily due to reduction in pulmonary pressure, in selective patients, changes in ventilation-perfusion relationships could account for some of the increase in oxygenation. The presence of significant methemoglobinemia in two patients (7% and 4.5%) when the infants' iNO dose was increased to 80 ppm highlights the importance of careful monitoring for toxicity. Further studies are needed to define the best dosage and duration of iNO. While iNO shows great promise in the treatment of PPHN, randomized controlled trials are needed to delineate in which infants iNO use is indicated.